Teva

News

Laquinimod failure is bad news for Teva's MS hopes

Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.

News

AZ hopes to boost respiratory pipeline with Pieris deal

AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech Pieris Pharmaceuticals.

News

FDA approves Teva's Huntington's Disease drug

First treatment approved for Huntington's Disease in almost a decade.

News

Teva files orphan blockbuster hope in tardive dyskinesia

SD-809 will be vital for Teva if approved.

Views & Analysis

Orphan drugs will fuel pharma's future - and a pricing pushb...

Evaluate predicts sales could approach $8bn if approved.

News

Mylan settles narcolepsy drug pay-for-delay case

Payment ends decade of litigation.

Laquinimod failure is bad news for Teva's MS hopes

AZ hopes to boost respiratory pipeline with Pieris deal

FDA approves Teva's Huntington's Disease drug

Teva files orphan blockbuster hope in tardive dyskinesia

Orphan drugs will fuel pharma's future - and a pricing pushb...

Mylan settles narcolepsy drug pay-for-delay case

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Teva

Editor's Picks